Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mibampator. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 known ✓ | P48058 | 17/20 | 1.00 |
| ▸ | GRIA2 known ✓ | P42262 | 3/20 | 0.59 |
| ▸ | GRIA1 known ✓ | P42261 | 1/20 | 0.59 |
| ▸ | GRIA3 known ✓ | P42263 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mibampator SCHEMBL6660037 | 1.00 | GRIA4 (1.00) | GRIA4GRIA2GRIA1GRIA3POLB | |
| Mibampator SCHEMBL3074747 | 1.00 | GRIA4 (1.00) | GRIA4GRIA2GRIA1GRIA3POLB | |
| SCHEMBL6563305 | 0.96 | GRIA4 (0.92) | GRIA4GRIA2GRIA1GRIA3POLB | |
| SCHEMBL5877913 | 0.93 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6563303 | 0.89 | GRIA4 (0.80) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5878077 | 0.88 | GRIA4 (0.79) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6565213 | 0.88 | GRIA4 (0.79) | GRIA4GRIA2GRIA1GRIA3POLB | |
| SCHEMBL719605 | 0.86 | GRIA4 (0.76) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL719606 | 0.86 | GRIA4 (0.76) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL5878035 | 0.85 | GRIA4 (0.74) | GRIA4GRIA2GRIA1GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | claimed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20230126310-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | FRAUNHOFER GES FORSCHUNG (DE) | 2023-04-27 | — | — | US | claimed |
| EP-4126234-A1 | COMPOSITIONS FOR CORONAVIRUS INFECTION TREATMENT AND/OR PREVENTION | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2023-02-08 | — | — | EP | claimed |
| WO-2005013961-A1 | COMBINATION THERAPY FOR TREATMENT OF COGNITIVE DISORDERS OR PSYCHOSES | ELI LILLY AND COMPANY (US) | 2005-02-17 | — | — | WO | claimed |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | BLEAKMAN DAVID (US) | 2004-11-25 | — | — | US | claimed |
| EP-1438036-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2004-07-21 | — | — | EP | claimed |
| US-20030225163-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-04 | — | — | US | claimed |
| EP-1311474-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-05-21 | — | — | EP | claimed |
| US-20030092770-A1 | Combination therapy for treatment of depression | ELI LILLY AND COMPANY | 2003-05-15 | — | — | US | claimed |
| WO-2003032974-A2 | USE OF SULFONAMIDE DERIVATIVES AS PHARMACEUTICALS COMPOUNDS | ELI LILLY AND COMPANY (US) | 2003-04-24 | — | — | WO | claimed |
| EP-1292311-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2003-03-19 | — | — | EP | claimed |
| WO-2001089530-A2 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | claimed |
| WO-2001090057-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | claimed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| WO-2001089530-A2 | COMBINATION THERAPY FOR TREATMENT OF DEPRESSION COMPRISING AN ANTIDEPRESSANT AND AN AMPA RECEPTOR POTENTIATOR | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
| WO-2001089510-A2 | USE OF AN AMPA RECEPTOR POTENTIATOR FOR THE TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225163-A1 | Sulfonamide derivatives | GRIN1, SLC1A2, GRIN2A | GRIA4 17/4885GRIA2 10/4885GRIA1 8/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | GRIA4 211/4885GRIA2 312/4885GRIA1 193/4885 |
| US-20030092770-A1 | Combination therapy for treatment of depression | GRM2, GRIK2, GRIN2A | GRIA4 18/4885GRIA2 19/4885GRIA1 23/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | GRIA4 22/4885GRIA2 25/4885GRIA1 20/4885 |
| US-20040235957-A1 | Use of sulfonamide derivatives as pharmaceuticals compounds | GABRE, SCN2A, SCN1A | GRIA4 212/4885GRIA2 176/4885GRIA1 324/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | GRIA4 602/4885GRIA2 809/4885GRIA1 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.